Tackling Private Corruption in Pakistan's Pharmaceutical Sector

(July 2018 - )

The Collective has secured a grant from the SOAS Anti-Corruption Evidence research consortium (SOAS-ACE) to undertake research on private sector corruption. The project focuses on Pakistan's pharmaceutical sector, which is currently valued at approximately USD$3 billion and comprises more than 750 firms. Corruption in the pharmaceutical sector in Pakistan has multiple negative impacts on development. It inhibits growth and dynamism in the economy - as an illustration, we compare Pakistan's export performance with Jordan and India and find Pakistan lagging far behind. Moreover, corruption also leads to higher out-of-pocket expenditures for consumers as well as putting pressure on health care services through repeat patients stretching scarce resources. The research project will examine different facets of corruption in this sector in order to find feasible anti-corruption strategies that increase the quality of available pharmaceuticals and encourage a dynamic economic sector.
Publications and Papers
  1. Kabeer Dawani and Asad Sayeed, Pakistan’s Pharmaceutical Sector: Issues of Pricing, Procurement and the Quality of Medicines. SOAS University of London: Anti-Corruption Evidence (ACE) Research Consortium Working Paper 012. August 2019.

    Keywords: Corruption, Economy, Health

  2. Kabeer Dawani, Low Cost, Low Access? A Misplaced Focus on Drug Pricing in Pakistan. Collective Blog. June 2019.

    Keywords: Economy, Health

  3. Kabeer Dawani, The hike in drug prices may be painful, but it’s necessary. Dawn. May 2019.

    Keywords: Economy, Health